The Oxford Science Park and its occupiers gathered together recently to celebrate successes and progress over recent months – a period in which the importance of science and technology companies in keeping the population healthy became clearer than ever.
Companies from across the Park, including LRE System, Oxford Endovascular, Oxford Vacmedix, OXGENE, Oxsonics Therapeutics, Physiomics, ProImmune and Sitryx, chatted to attendees from Advanced Oxford, Oxford City Council and Magdalen College Oxford. There was much discussion of how companies had expanded over the period of the pandemic, as investment into pharmaceutical, biotechnology and medical technology companies across a range of diseases continued strongly. Some companies have doubled their headcount.
Congratulating occupiers on their progress, The Oxford Science Park CEO Rory Maw highlighted the 2021 IPOs of Vaccitech, Oxford Nanopore and Exscientia as clear indicators of the innovation and value creation in the Oxford ecosystem. This is underscored by the tally of funds raised by tenants since the beginning of 2020 – an impressive £2bn+. ATDBio’s sale to Biotage of Sweden, which will bring about accelerated expansion of the UK company’s activities, was also hailed as a success story. The family-run company was founded in 2004 by Professor Tom Brown (Snr), one of the world’s leading nucleic acids chemists, and makes products for a broad range customers which include some of the most significant biotech and pharma companies globally.
TOSP’s CEO also discussed the impact of the newly signed joint venture between Magdalen College and Singaporean long-term investor GIC, now co-owners of the Park. The increased capital available means that development plans for a range of new laboratory and office buildings can be accelerated – for example the new innovation centre on Plot 18 expected to open at the beginning of 2024. This is in conjunction with Plot 16 where the first building will be finished in 2023.